Top Mover
IDEXX Laboratories Surges 20% After Q3 Earnings Beat and Raised Full-Year Guidance
Read this in the Market Flux appIDEXX Laboratories, Inc. $IDXX
$671.77+21.74%as of publication
- 5D Change
- +17.81%
- Market Cap
- $43.42B
IDEXX Laboratories posted third-quarter 2026 revenue of $1.214 billion, up 10% as reported and on an organic basis, beating the average analyst estimate by 2.21%. Earnings per diluted share came in at $4.01, an increase of 18% as reported and 22% on a comparable basis, surpassing the consensus estimate by $0.24, or roughly 7.3%. Growth was driven by its Companion Animal Group, which also grew 10% as reported and organic, with expansion in diagnostic utilization and a record placement of over 1,900 new inVue Dx analyzers, even as U.S. clinic visit traffic remained soft.
The company raised its full-year 2026 guidance, citing acquisition impacts and strong CAG Diagnostics recurring revenue performance. The updated outlook calls for revenue of $4.74 billion to $4.77 billion and EPS of $14.96 to $15.16 for the full year.
Shares surged approximately 20% in Monday's regular session, with the stock trading around $662, making IDEXX the top performer in both the S&P 500 and Nasdaq 100 on the day. The stock had been down about 4% year to date heading into the report.
© AI-generated summary is provided by Market Flux
Sources
- MarketWatchIdexx Laboratories Shares Gain on Outlook Boost, Higher 3Q Results
- Yahoo FinanceIDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary
- Seeking AlphaIDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript
- Business WireIDEXX Laboratories Announces Third Quarter Results
- NasdaqIDEXX Laboratories Inc Q3 Profit Climbs
- InvestingForm 8K IDEXX Laboratories Inc For: 2 November
- BriefingcomGapping up: $INO +266.3% $PERI +31.2% $IDXX +5.9% $XPEV +5.3% $AVR +4.7% Gapping down: $NSSC -17.6% $OFRM -11.7% $KOS -8.9% $CHKP -6.3%
- ZerohedgePremarket movers: Nvidia and Alphabet lead gains among the Mag 7 as tech stocks are set to rebound: Nvidia (NVDA) +1.0%, Alphabet (GOOGL) +0.7%, after opening the books on a seven-part offering spanning maturities from two to 19 years (Amazon +0.3%, Tesla +0.7%, Microsoft +0.4%, Meta Platforms (META) -0.6%, Apple (AAPL) -0.1%). Check Point Software (CHKP) drops 6% after the company reported revenue for the third quarter that missed the average analyst estimate. Crowdstrike (CRWD) rises 3% after Deutsche Bank upgraded the security software company to buy, seeing tailwinds related to AI. Estee Lauder (EL) gains 3% after reporting better—than-expected earnings and raising its outlook, the latest sign the beauty conglomerate’s turnaround effort is winning over consumers. Floor & Decor (FND) slips 1.6% after Goldman Sachs cut the recommendation to sell. The downgrade came after the flooring products supplier said comparable sales are down to start the fourth quarter. Geo Group (GEO) gains 3% after securing a contract from US Immigration and Customs Enforcement to provide support services at the 2,329-bed Big Spring Complex in Texas. Idexx Labs (IDXX) rises 6% after the animal health firm boosted its revenue guidance for the full year, following results for the third quarter that beat the average analyst estimate. Inovio Pharmaceuticals (INO) rallies 50% after the biotech got accelerated FDA approval for Voceryq, an immunotherapy to treat adults with recurrent respiratory papillomatosis. Kosmos Energy (KOS) falls 7% after the oil and gas company reported third-quarter adjusted earnings per share that missed the average analyst estimate as weather weighed on results. Marvell Technology (MRVL) climbs 1% after reaching a deal to buy Lumentum at an enterprise value $115 billion in a race to capitalize on the artificial intelligence boom. Lumentum (LITE) slips 1%. Okta (OKTA) rises 2% as the stock will replace Kenvue Inc. in the S&P 500 effective Wednesday. Once Upon a Farm (OFRM) falls 12% after the children’s nutritional food company said it will host a business update conference call/webcast at 8:30am NY time to discuss the company’s voluntary recall of its Tractor Wheels soft-baked bars due to potential choking hazard that was issued on Oct. 30.
Show 8 more
- OpenOutcrier$IDXX (+7.9% pre) IDEXX Labs beats estimates, raises guidance as stock gains
- BenzingaIDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday
- BarronsonlineIdexx Laboratories reported strong growth in veterinary diagnostics, offsetting sluggish industry demand.
- JonnajarianRebel’s Edge 🏴☠️ 1pm Line up: #VIX $IDXX $MPWR $MRVL $LITE $ULCC Midterm elections tomorrow, who controls Congress? #WANNABET 🏈 NAJARIAN SPORTS 🏴☠️ with @petenajarian Did USC just stun No. 2 Ohio State, and is college football parity closer all the time? Are the Vikings 6-1 without beating a team with a winning record, now that no NFL team is undefeated? #ITSNOTANOPTION 📙
- TheflynewsMidday Fly By: S&P warns on Meta's credit, Marvell to acquire Lumentum $ETR $ORCL $COIN $CRWD $FND $RDDT $MAR $IDXX $L $EL $EVGO $NXT $RIVN $OFRM $XMAX $TSLA $ALK $AMZN $META $MC $CG $KKR $MRVL $LITE $SPCX $T $TMUS
- MarketRebelsSTARTS NOW Rebel’s Edge 🏴☠️ 1pm Line up: #VIX $IDXX $MPWR $MRVL $LITE $ULCC Midterm elections tomorrow, who controls Congress? #WANNABET 🏈 NAJARIAN SPORTS 🏴☠️ with @petenajarian Did USC just stun No. 2 Ohio State, and is college football parity closer all the time? Are the Vikings 6-1 without beating a team with a winning record, now that no NFL team is undefeated? #ITSNOTANOPTION 📙
- 24/7 Wall StreetIDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
- BPharmCatalyst$DRUG faced an FDA partial clinical hold on its Phase 2 BMB-101 trial for DEE due to mouse toxicity findings and missing juvenile toxicology and pediatric PK data. While other programs are unaffected, resuming U.S. DEE development may require more preclinical testing, causing timeline uncertainty. $INO $KPTI $JAGX $IDXX $GNTA $DRUG $NMRA $ATYR $ESLA $NRSN For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section